Firstly, tirzepatide results in greater WL and HbA1c reduction than other GLP‐1 based therapies, even at the dose of 5 mg once weekly (the lowest approved dose for obesity and T2D management).50 The gene discussed is GLP1R; the disease is obesity disorder.